We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $97.15 · 27 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Insider Sell: Andrew Dahl Sells Shares of Edwards Lifesciences C - GuruFocus
Insider Sell: Andrew Dahl Sells Shares of Edwards Lifesciences C GuruFocus
Geode Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Geode Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW MarketBeat
Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock MarketBeat
Edwards Lifesciences (EW) SVP records small open-market stock sale - Stock Titan
Edwards Lifesciences (EW) SVP records small open-market stock sale Stock Titan
Edwards Lifesciences (NYSE: EW) affiliate reports two 13,000-share sales - Stock Titan
Edwards Lifesciences (NYSE: EW) affiliate reports two 13,000-share sales Stock Titan
Edwards Lifesciences (NYSE: EW) files Form 144 for proposed common sale - Stock Titan
Edwards Lifesciences (NYSE: EW) files Form 144 for proposed common sale Stock Titan
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 23. | After market close (AMC) | $0.74 | — | — | $1.7B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.61 | — | — | $1.41B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $6.29 | — | — | $4.05B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.19 | — | — | $2.7B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 27. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 04. 25. | Evercore ISI Group | — | Maintain | Outperform → Outperform | — | Evercore ISI Group: Outperform |
| 2026. 04. 25. | Truist Securities | — | Maintain | Hold → Hold | — | Truist Securities: Hold |
| 2026. 04. 24. | Canaccord Genuity | — | Maintain | Hold → Hold | — | Canaccord Genuity: Hold |
| 2026. 04. 24. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 04. 24. | Baird | — | Maintain | Neutral → Neutral | — | Baird: Neutral |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,826,537 | $146.27B | 0.27% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,051,535 | $84.21B | 0.07% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 444,367 | $37.88B | 0.06% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 391,386 | $33.37B | 0.05% | — | New position |